在患有癌症的患者中,素纤维素素水平升高
Tom Arfman1, Valentina Zollet2,3, Nick van Es4,5
1Department of Molecular Hematology Sanquin Research and Landsteiner Laboratory Amsterdam The Netherlands.
EJHaem
|February 26, 2024
概括
癌症患者表现出显著增加的氨酸纤维素水平,这种变化与氨基氨基酸减弱酶4 (PAD4) 活性有关. 这一发现突出了与癌症相关的静脉血栓栓塞 (VTE) 风险的潜在生物标志物.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 血液学 血液学 血液学
背景情况:
- 丁氨酸脱酶4 (PAD4) 是由中性粒细胞释放的一种酶.
- 在血蛋白上,PAD4催化了氨酸转化为氨酸的过程.
- 纤维素原的素化是一种后翻译性修饰,具有潜在的疾病影响.
研究的目的:
- 开发和验证一种测量方法来定量素化纤维素原.
- 调查癌症患者的素纤维素水平,特别是那些有静脉血栓塞栓症 (VTE) 风险的人.
主要方法:
- 开发一种新型测定方法,使用生物素结合的基 (biotin-PG) 来选择性地标记素残留物.
- 分析来自多中心前性队列研究的患者样本.
- 在癌症患者,健康捐赠者和正常人血之间比较素纤维素水平.
主要成果:
- 开发的试验成功量化了素纤维素原.
- 与健康对照组相比,癌症患者的林纤维素水平中位数增加了2倍.
- 在癌症患者和正常人体血中观察到素纤维素的升高.
结论:
- 纤维素原的素化是癌症患者中普遍存在的翻译后修饰.
- 林纤维素水平升高可能成为癌症中的生物标志物.
- 需要进一步的研究来探索素纤维素素在与癌症相关的静脉瘤中所扮演的角色.
更多相关视频
10:05Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins
Published on: August 7, 2014
13.9K
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
7.2K
相关概念视频
Selectins
3.3K
Cell adhesion is an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
